{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-14400", "open" : "1247664641", "close" : "1247688041", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}

Send us feedback. Tell us what you think about the new Article Page. Send us feedback

globenewswire

Infinity to Present At JP Morgan Healthcare Conference

  • Press Release
  • Source: Infinity Pharmaceuticals, Inc.
  • On Tuesday January 6, 2009, 8:30 am EST

CAMBRIDGE, Mass., Jan. 6, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (NasdaqGM:INFI - News), an innovative cancer drug discovery and development company, today announced that Steven H. Holtzman, chair and chief executive officer, will be presenting a company overview at the 27th Annual JP Morgan Healthcare Conference. Infinity's presentation will take place on Wednesday, January 14, 2009 at 1:30 p.m. (PST) (4:30 p.m. EST) at the Westin St. Francis in San Francisco, Calif.

A live webcast of Infinity's presentation will be accessible on the company's website at http://www.infi.com.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.

Contact:

          Infinity Pharmaceuticals, Inc.
          Monique Allaire
          617-453-1105
          Monique.Allaire@infi.com
          http://www.infi.com

Related Headlines

Top Stories

Related Message Boards

Sponsored Links

Copyright © 2009 GlobeNewswire. All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.